Insmed Inc Stock Analysis

Insmed Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 5.55. Insmed Inc had not issued any dividends in recent years. The entity had 1:10 split on the 3rd of March 2011. Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey. Insmed operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 613 people. To learn more about Insmed Inc call MBA JD at 908 977 9900 or check out https://www.insmed.com.

Insmed Inc Investment Alerts

Insmed Inc Upcoming and Recent Events

Insmed Largest EPS Surprises

View All Earnings Estimates

Insmed Environmental, Social, and Governance (ESG) Scores

Insmed Stock Institutional Investors

Note, although Insmed's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Insmed Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 13.2 B.

Insmed Profitablity

The company has Profit Margin (PM) of (2.52) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.13.

Management Efficiency

Insmed Inc has return on total asset (ROA) of (0.2605) % which means that it has lost $0.2605 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.9075) %, meaning that it created substantial loss on money invested by shareholders. Insmed's management efficiency ratios could be used to measure how well Insmed manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Equity is likely to grow to 2.37, while Return On Tangible Assets are likely to drop (0.70). At this time, Insmed's Intangibles To Total Assets are very stable compared to the past year. As of the 22nd of November 2024, Debt To Assets is likely to grow to 0.91, though Net Tangible Assets are likely to grow to (127.7 M).

Technical Drivers

As of the 22nd of November, Insmed retains the insignificant Risk Adjusted Performance, standard deviation of 2.57, and Market Risk Adjusted Performance of (0.02). Insmed technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Insmed Inc market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Insmed is priced fairly, providing market reflects its last-minute price of 73.81 per share. Given that Insmed Inc has information ratio of (0.06), we strongly advise you to confirm Insmed Inc's regular market performance to make sure the company can sustain itself at a future point.

Insmed Inc Price Movement Analysis

Insmed Inc Insider Trading Activities

Insmed Outstanding Bonds

Insmed Predictive Daily Indicators

Insmed Corporate Filings

Insmed Forecast Models

Insmed's time-series forecasting models are one of many Insmed's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Insmed's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Insmed prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Insmed shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Insmed. By using and applying Insmed Stock analysis, traders can create a robust methodology for identifying Insmed entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Insmed analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Insmed analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Insmed Inc stock analysis indicators help investors evaluate how Insmed stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Insmed shares will generate the highest return on investment. By understating and applying Insmed stock analysis, traders can identify Insmed position entry and exit signals to maximize returns.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.